Image source: Getty Images.
There’s no question that chimeric antigen receptor (CAR) T cell therapies have sparked plenty of attention from investors. But that attention hasn’t been shared equally among the different companies working on CAR drugs. Bellicum Pharmaceuticals (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) prove that point.